# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Johnny Cash (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML004-SYN
- Date: 2026-05-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gideon Hale, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month diabetes, blood pressure, and eye pressure review. **S**

## History of present illness

Mr. Cash returns for his three-month review, nine weeks after sitagliptin and midodrine 2.5 mg were started and five weeks after his annual wellness visit. His fasting home readings now run 120 to 150 mg/dL, with none below 70. He is less lightheaded than before midodrine, but he still feels faint for a minute or two after getting up in the morning and after lunch, and he has had no falls. He takes the last midodrine by mid-afternoon and has no scalp tingling or trouble passing urine. He has started physical therapy for gait and balance, and the low-vision home visit is booked. He uses both eye drops every day without stinging. No eye pressure check was done between visits. He is writing and recording at home. **S**

| Element | Detail |
|---|---|
| Interval change | Less lightheaded; still briefly faint after rising and after lunch; no falls |
| Home glucose | Fasting 120 to 150 mg/dL; none below 70 |
| Midodrine tolerance | Last dose by mid-afternoon; no scalp tingling or urinary retention |
| Rehabilitation | Physical therapy started; low-vision home visit booked |
| Eye drops | Latanoprost and dorzolamide daily; no stinging |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down 0.7 kg since the wellness visit; no fever |
| Eyes | Positive | Tunnel vision and poor vision in dim light, unchanged; no eye pain or redness |
| Cardiovascular | Positive | Briefly faint after rising and after lunch; no fainting or chest pain |
| Genitourinary | Negative | No difficulty passing urine |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

6 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Sitagliptin 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime **S**
- Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily **S**
- Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/76 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 96% on room air; weight 93.5 kg; BMI 26.5 kg/m². All vital signs are synthetic.

HbA1c: 7.7% (high); LDL cholesterol: 74 mg/dL; ALT: 27 U/L; Intraocular pressure, right eye: 15 mmHg; Intraocular pressure, left eye: 16 mmHg; PHQ-2: 0. All results are synthetic.

## Change since baseline

- HbA1c: 8.6% (high) at baseline, 7.7% (high) at this visit **S**
- LDL cholesterol: 128 mg/dL (high) at baseline, 74 mg/dL at this visit **S**
- ALT: 24 U/L at baseline, 27 U/L at this visit **S**
- Intraocular pressure, right eye: 22 mmHg (high) at baseline, 15 mmHg at this visit **S**
- Intraocular pressure, left eye: 24 mmHg (high) at baseline, 16 mmHg at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 1 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and well; walks with a cane |
| Eyes | Conjunctivae quiet; eye pressure 15 mmHg right and 16 mmHg left by applanation at the eye clinic today |
| Cardiovascular | Regular rhythm; blood pressure 146/82 mmHg lying, 136/76 mmHg seated, and 114/70 mmHg after three minutes standing, with lightheadedness |
| Feet | Skin intact; no ulcers or calluses; sensory loss to the ankles unchanged; protective shoes |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Neurogenic orthostatic hypotension** (I95.1). Standing systolic pressure 114 mmHg on midodrine 2.5 mg, with symptoms after rising and after meals. Lying pressure 146/82 mmHg leaves room to raise the dose. **S**
   - Increase midodrine to 5 mg on waking, at midday, and mid-afternoon, with the last dose at least four hours before bed.
   - Smaller, lower-carbohydrate lunches to reduce the fall in pressure after meals.
   - Lying, seated, and standing pressure at the six-month review.
2. **Type 2 diabetes with diabetic autonomic neuropathy** (E11.43). HbA1c 7.7%, down from 8.6% and close to his goal below 7.5%, with no hypoglycemia. **S**
   - Continue metformin and sitagliptin.
   - HbA1c at the six-month review.
3. **Hyperlipidemia** (E78.5). LDL 74 mg/dL, down from 128 on atorvastatin 40 mg. That is a 42 percent fall, short of the 50 percent expected on a high-intensity dose and just above the goal below 70. He reports taking it every day. ALT 27 U/L, normal. **S**
   - Continue atorvastatin 40 mg and reinforce daily use.
   - Add ezetimibe if LDL is still 70 or more at the annual review.
   - Lipid panel at the annual review.
4. **Primary open-angle glaucoma, severe stage** (H40.1133). Eye pressures 15 and 16 mmHg, down from 22 and 24, meet the eye clinic's target of 16 or less. Neither drop lowers blood pressure or heart rate. **S**
   - Continue latanoprost and dorzolamide.
   - OCT and visual fields at six months with the eye clinic.
5. **Immunization and preventive care**. PCV20 was given at the first visit; recombinant zoster vaccine was planned for today. **S**
   - Recombinant zoster vaccine dose 1 given today; dose 2 in two to six months.
   - Hepatitis C antibody drawn with today's tests, as planned at the wellness visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HbA1c | Every 3 months until at goal or after a therapy change; every 6 months when stable | Completed today | 7.7%, down from 8.6%; not yet at goal, so repeat in three months |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after a statin starts or changes | Completed today | LDL 74 mg/dL, a 42 percent fall. Drawn at 13 weeks, one week after the window closed, because the panel was scheduled for this review instead of inside the window: a minor deviation from the protocol. No harm resulted; there was no dose decision that an earlier result would have changed |
| Laboratory | ALT | Once before a statin; afterward only for symptoms | Completed today | 27 U/L, normal; no further routine checks |
| Laboratory | ALT, AST, and platelets for FIB-4 | At diagnosis and yearly | Deferred | FIB-4 could not be calculated at intake because no platelet count was drawn with the hemoglobin, a deviation from the protocol. ALT and AST were normal at intake and ALT is normal today, so missed liver scarring is unlikely; AST and a platelet count are added to the annual tests |
| Laboratory | Lipoprotein(a) | Once in adulthood | Deferred | Not yet measured, a deviation from the protocol. It would not change treatment now, since he already takes a high-intensity statin; added to the annual lipid panel |
| Examination | Blood pressure, weight, and BMI | Every visit | Completed today | Seated 136/76 mmHg; weight 93.5 kg |
| Examination | Lying, seated, and standing blood pressure | Every visit | Completed today | Lying 146/82, standing 114/70 mmHg; no supine hypertension |
| Examination | Foot examination (inspection, pulses, monofilament) | Every visit with loss of protective sensation | Completed today | No ulcer; sensory loss unchanged |
| Examination | Tonometry (eye pressure) | Every glaucoma visit; 4 to 6 weeks after adding a drop | Completed today | 15 mmHg right and 16 mmHg left, at target. This is the first check since dorzolamide was added three months ago; the check at four to six weeks was missed (see the four-week note). The pressure has reached target, and the six-month OCT and fields will show whether the delay cost any nerve tissue |
| Examination | Drop adherence, ocular surface, and systemic effects of glaucoma drops | Every visit | Completed today | Both drops used daily; no stinging; no effect on pulse or blood pressure |
| Imaging | OCT of the optic nerve and nerve fiber layer, and visual fields | Every 6 months in severe glaucoma | Due | At the six-month review with the eye clinic |
| Survey | Hypoglycemia review and home glucose log | Every visit | Completed today | No readings below 70 mg/dL |
| Survey | Depression screen (PHQ-2) | At least yearly | Completed today | Score 0 |
| Survey | Tobacco use | Every visit | Completed today | No tobacco use |
| Medication safety | Midodrine safety: lying pressure, timing, and urinary retention | Every visit on midodrine | Completed today | Lying 146/82 mmHg; last dose by mid-afternoon; no retention |
| Medication safety | Vaccination review | Yearly, and as doses fall due | Completed today | Recombinant zoster dose 1 given today; RSV, COVID-19, and tetanus remain due from the wellness visit |
| Referral | Physical therapy and low-vision rehabilitation | After a fall-risk finding | Completed today | Physical therapy under way; low-vision home visit booked |
| Self-management | Diet, orthostatic measures, and foot self-care | Every visit | Completed today | Smaller lunches added; other measures continue |

## Goal progress

- Reach an HbA1c below 7.5% without hypoglycemia by the six-month review. In progress; target 2026-08-14. **S**
- No falls and a standing systolic pressure of 100 mm Hg or more by the six-month review. In progress; target 2026-08-14. **S**
- Lower intraocular pressure to 16 mm Hg or less in each eye by the three-month review. Outcome by 2026-05-29: Pressure 15 mm Hg right and 16 mm Hg left at three months. **S**
- LDL cholesterol below 70 mg/dL by the six-month review. In progress; target 2026-08-14. **S**

## Medication changes

- Stopped: Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM **S**
- Started: Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM **S**

## Guideline basis

- Standards of Care in Diabetes—2025 (2025), American Diabetes Association
- Primary Open-Angle Glaucoma Preferred Practice Pattern (2025), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Six-month diabetes review with HbA1c, a basic metabolic panel, urine albumin-creatinine ratio, eye pressure, OCT, and visual fields. **S**
- Next scheduled visit 2026-08-14: six-month diabetes review with glaucoma imaging. **S**
